Introduction

The Archer® FusionPlex® ALL Kit is a targeted next-generation sequencing assay that detects and identifies fusions, point mutations and expression levels from RNA input. The kit is comprehensive in nature, targeting 81 genes associated with Acute Lymphoblastic Leukemia, including all recurrent Ph-Like ALL fusion events. Using Archer’s proprietary Anchored Multiplex PCR™-based enrichment, fusions of all genes in this kit can be identified in a single sequencing assay, even without prior knowledge of fusion partners or breakpoints. Additionally, select genes are targeted for molecular barcode-enabled relative expression level detection and point mutation coverage.

For Research Use Only. Not for use in diagnostic procedures.

Highlights

  • Simultaneously interrogate hundreds of potential gene fusion events and relevant point mutations with under 2 million reads
  • Molecular barcode-enabled relative expression level detection in select genes
  • Expression imbalance confirmation for key fusions
  • Wide sample type compatibility including FFPE
  • Covers all recurrent PH-like ALL fusions




Kit Targets

FusionPlex Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Kit targets

  •  Fusion, splicing or exon skipping
  •  Mutation
  •  Expression
  •  Expression Imbalance
ABL1
 
EBF1
   
JAK1
   
NUP214
   
SETD2
   
ABL2
   
EPOR
   
JAK2
  
NUP98
   
SH2B3
   
AICDA
   
ETV6
  
JAK3
   
PYRY8
   
SOX11
   
BCL11B
   
EZH2
   
KDM6A
   
PAG1
   
STAT3
   
BCL2
 
FBXW7
   
KLF2
   
PAX5
  
STAT5B
   
BCL6
  
FGFR1
   
KMT2A
   
PBX1
  
STIL
   
BCR
   
FLT3
  
KRAS
   
PDCD1
   
TAL1
  
BLNK
   
HOXA10
   
LMO1
   
PDCD1LG2
  
TCF3
   
BRAF
   
HOXA9
   
LYL1
   
PDGFRA
  
TLX1
   
CD274
   
IDH1
   
MLLT4
   
PDGFRB
   
TLX3
   
CHD1
   
IDH2
   
MPL
   
PICALM
   
TYK2
   
CREBBP
  
IKZF1
   
MYC
  
PTK2B
   
WT1
  
CRLF2
 
IKZF2
   
NF1
   
PTPN11
   
ZCCHC7
   
CSF1R
   
IKZF3
  
NOTCH1
  
RAG1
   
CTLA4
   
IL7R
   
NRAS
   
RAG2
   
DNM2
   
IRF4
   
NT5C2
   
RUNX1
  
DNTT
   
IRF8
   
NTRK3
  
SEMA6A
   

Note: Fusions involving BCR and TCR loci, including IGH, IGL and IGK, are targeted for expression and may not be explicitly called as a fusion because these often do not result in chimeric transcripts.


Superior kit performance


Feature Specification
Input RNA required 50-200ng
Time required 8.5 hours
Hands-on time 3.5 hours
Sample type(s) Blood, fresh frozen, FFPE
# of GSP2s 506
Unique moleculer on-target >95%
Coverage uniformity > 20% mean >99%
% Bases at 50x unique molecule coverage >99%
Platform Illumina® or Ion Torrent™
Recommended # of reads 1.5 Million

Note: As observed on multiple lots using 50ng gDNA input. DNA input allows for a better measurement of the behavior across primers and can be be used to assess coverage uniformity. RNA can vary due to expression levels.


Ph-like Acute Lymphoblastic Leukemia

The FusionPlex ALL kit includes targets found in Philadelphia chromosome-like acute lymphoblastic leukemia (Ph-like ALL), which is characterized by modifications in lymphoid transcription factor genes, poor outcomes, and a gene-expression profile similar to that of BCR-ABL1 ALL. Recent clinical and xenograft studies have revealed that the Ph-like ALL gene expression profile includes multiple genomic alterations, which are listed in the table below.

Recurrent kinase fusions identified in Ph-like Acute Lymphoblastic Leukemia

KinaseNumber of gene partnersFusion partner genes
ABL17ETV6, NUP214, RCSD1, RANBP2, SNX2, ZMIZ1
ABL23PAG1, RCSD1, ZC3HAV1
CSF1R1SSBP2
PDGFRB4EBF1, SSBP2, TNIP1, ZEB2
CRLF22IGH, P2RY8
JAK210ATF7IP, BCR, EBF1, ETV6, PAX5, PPFIBP1, SSBP2, STRN3, TERF2, TPR
EPOR2IGH, IGK
PTK2B2KDM6A, STAG2

*FusionPlex ALL Kit will only detect an EPOR truncation

How to contact us

Address

2477 55th Street, Suite 202

Boulder, CO 80301

Phone

Phone: (877) 771 1093

Phone: (303) 357 9001

All content © 2017 ArcherDX, Inc.

For Research Use Only. Not for use in diagnostic procedures. For Research Use Only. Not for use in diagnostic procedures.